Tibotec New Study Compares Once-Daily Versus Twice-Daily Prezista
In the new study of treatment-experienced HIV-1-infected adults with no Prezista resistance-associated mutations (RAMs), 72% of patients in the Prezista/ritonavir (800/100 mg) once-daily arm achieved undetectable viral loads
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.